Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01629758 | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | PHASE1 | COMPLETED | 33 | — | — | Jun 1, 2012 | Dec 1, 2014 | Mar 6, 2015 | 5 | United States |
| Arm | Type | Description |
|---|---|---|
| Part 1-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 1-Arm B: BMS-982470 (3 times/week) + BMS-936558 | EXPERIMENTAL | Dose Escalation BMS-982470 10, 30, 50, 75 or 100 µg/kg Solution, Intravenous, During each 6 week cycle: 3 times/week during weeks 1 and 3, Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Part 2-Arm A: BMS-982470 (weekly x 4) + BMS-936558 | EXPERIMENTAL | Cohort Expansion BMS-982470 (dose selected in Part 1) Solution, Intravenous, During each 6 week cycle: weekly x 4 (i.e during weeks 1 through 4), Up to 2 years + BMS-936558 3 mg/kg Solution, Intravenous, During each 6 week cycle: every other week (i.e during weeks 1, 3, and 5), Up to 2 years |
| Name | Type | Description |
|---|---|---|
| Denenicokin | BIOLOGICAL | - |
| Nivolumab | BIOLOGICAL | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * All subjects will have locally advanced or metastatic solid tumors * For Part 2 (Cohort Expansion): * Tumor types will be restricted to clear cell renal cell carcinoma (cc...